Teva Provides Additional Detail on Proposed Acquisition of Mylan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Teva Pharma (TEVA) Announces Completion of $3.5B Auspex Pharma Acquisition
May 5, 2015 9:03 AM EDTTeva Pharma (NYSE: TEVA) announced that the acquisition of Auspex Pharmaceuticals, Inc. (NASDAQ: ASPX) has been completed through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Tevas revenue and earnings growth profile and strengthen its core central nervous system franchise.
Auspex is an innovative biopharmaceutical company specializing in applying deuterium chemistry to known... More
Teva Pharma (TEVA) Makes Additional Push for Combination with Mylan (MYL)
May 5, 2015 8:32 AM EDTTeva Pharma (NYSE: TEVA) announced that an updated investor presentation in connection with its proposed combination with Mylan N.V. (NASDAQ: MYL) is available on the Investor Relations section of the Companys website and will be filed with the Securities and Exchange Commission (SEC).
Erez Vigodman, President and CEO of Teva, commented, Our strong financial and operating performance demonstrates that great people, great products and world-class execution of our strategy are coming together in a powerful way at Teva. Teva has built the foundation for accelerated... More
